Akihiro Yoshimura

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Topics

Tyrosine Kinase

Stem Cell Transplantation

Epidermal Growth Factor Receptor

Top Venues

British journal of cancer

NPJ precision oncology

Respirology case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Haruka Kuno, Naoya Nishioka, Tadaaki Yamada, Yusuke Kunimatsu, Akihiro Yoshimura, Soichi Hirai, Shun Futamura, Taiki Masui, Masashi Egami, Yusuke Chihara, Takayama Koichi
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study. Cancers 16 (17) (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Akihiro Yoshimura, Mano Horinaka, Takeshi Yaoi, Hisako Ono, Kyoko Itoh, Tadaaki Yamada, Takayama Koichi, Toshiyuki Sakai
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. British journal of cancer 131 (2) (2024)
Shota Takei, Akihiro Yoshimura, Chie Yamamoto, Seita Kataoka, Nobutaka Kataoka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Tadaaki Yamada, Takayuki Takeda, Koichi Takayama
Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report. Respirology case reports 11 (9) (2023)
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Takayama Koichi
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ precision oncology 7 (1) (2023)
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Yuta Yamanaka, Hiroshige Yoshioka, Ryoichi Honda, Kiyoaki Uryu, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Tadaaki Yamada, Nobuyo Tamiya, Naoko Okura, Takahiro Yamada, Junji Murai, Shinsuke Shiotsu, Takayasu Kurata, Takayama Koichi
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study. Cancers 15 (20) (2023)
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Takayama Koichi
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ precision oncology 7 (1) (2023)
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Takayama Koichi
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ precision oncology 7 (1) (2023)
Rei Noguchi, Akihiro Yoshimura, Uchino Junji, Takayuki Takeda, Yusuke Chihara, Takayo Ota, Osamu Hiranuma, Hiroshi Gyotoku, Takayama Koichi, Tadashi Kondo
Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. Proteomes 11 (1) (2023)
Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei, Yuki Katayama, Makoto Hibino, Tadaaki Yamada, Takayama Koichi
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers 15 (17) (2023)
Rei Noguchi, Akihiro Yoshimura, Uchino Junji, Takayuki Takeda, Yusuke Chihara, Takayo Ota, Osamu Hiranuma, Hiroshi Gyotoku, Takayama Koichi, Tadashi Kondo
Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. Proteomes 11 (1) (2023)
Akihiro Yoshimura, Tadaaki Yamada, Masakuni Serizawa, Hisanori Uehara, Keiko Tanimura, Yusuke Okuma, Akito Fukuda, Satoshi Watanabe, Naoya Nishioka, Takayuki Takeda, Yusuke Chihara, Shinnosuke Takemoto, Taishi Harada, Osamu Hiranuma, Yukina Shirai, Takehito Shukuya, Akihiro Nishiyama, Yasuhiro Goto, Shinsuke Shiotsu, Kei Kunimasa, Kenji Morimoto, Yuki Katayama, Kenichi Suda, Tetsuya Mitsudomi, Seiji Yano, Hirotsugu Kenmotsu, Toshiaki Takahashi, Koichi Takayama
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. Cancer science (2022)
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, Takeshi Kitazaki, Akihiro Nishiyama, Masahiro Iwasaku, Yoshiko Kaneko, Uchino Junji, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Kohei Tanaka, Ryohei Kozaki, Seiji Yano, Takayama Koichi
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (9) (2020)
Rong Wang, Tadaaki Yamada, Kenji Kita, Hirokazu Taniguchi, Sachiko Arai, Koji Fukuda, Minoru Terashima, Akihiko Ishimura, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Koshiro Ohtsubo, Kaname Yamashita, Tomoyoshi Yamano, Akihiro Yoshimura, Koichi Takayama, Kyoichi Kaira, Yoshihiko Taniguchi, Shinji Atagi, Hisanori Uehara, Rikinari Hanayama, Isao Matsumoto, Xujun Han, Kunio Matsumoto, Wei Wang, Takeshi Suzuki, Seiji Yano
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature communications 11 (1) (2020)
Tatsuya Imabayashi, Uchino Junji, Akihiro Yoshimura, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Koichi Takayama
Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. Cancers 11 (3) (2019)
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Akihiro Yoshimura, Takayuki Takeda, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino, Koichi Takayama
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. Thoracic cancer 10 (3) (2019)
Akihiro Yoshimura, Tadaaki Yamada, Naoko Okura, Takayuki Takeda, Kazuki Hirose, Yutaka Kubota, Shinsuke Shiotsu, Osamu Hiranuma, Yusuke Chihara, Nobuyo Tamiya, Yoshiko Kaneko, Uchino Junji, Koichi Takayama
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. Cancers 11 (3) (2019)
Akihiro Yoshimura, Tadaaki Yamada, Taisuke Tsuji, Ryosuke Hamashima, Shinsuke Shiotsu, Tatsuya Yuba, Chieko Takumi, Junji Uchino, Noriya Hiraoka, Koichi Takayama
Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. Thoracic cancer 10 (3) (2019)
Akihiro Yoshimura, Chieko Takumi, Taisuke Tsuji, Ryosuke Hamashima, Shinsuke Shiotsu, Tatsuya Yuba, Yoji Urata, Noriya Hiraoka
Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report. Clinical case reports 6 (7) (2018)
Akihiro Yoshimura, Taisuke Tsuji, Yuka Kawaji, Yoshiko Hirakawa, Hitoji Uchiyama, Noriya Hiraoka
BK virus pneumonia following stem cell transplantation against diffuse large B-cell lymphoma. Respirology case reports 6 (7) (2018)